window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 1, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

respiratory R&D

  • Clinical Trials,Research & Development,Respiratory

    Tozorakimab meets primary endpoint in two Phase 3 COPD trials, showing reduction in exacerbations

    Tozorakimab has met its primary endpoint in two replicate Phase [...]

    March 27, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Ribbon CEO calls for faster adoption of AI and DNA synthesis to accelerate drug development
    Categories: Biotech, Digital Health, Research & Development
  • FDA signals continued access for desiccated thyroid extract products as manufacturers move toward biologics pathway
    Categories: Regulatory Affairs, Research & Development
  • Tozorakimab meets primary endpoint in two Phase 3 COPD trials, showing reduction in exacerbations
    Categories: Clinical Trials, Research & Development, Respiratory
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top